University of Arizona Department of Psychiatry
Tucson, Arizona, 85724, United States
NCT Number: NCT01570972
Multifamily group psychoeducation [MFG] and group cognitive behavioral therapy [GCBT] are evidence-based treatments for first episode psychosis. However, like all treatments for psychotic disorders, neither MFG nor GCBT are perfect-some individuals who receive these interventions still experience a worsening of psychotic symptoms. Clarifying the mechanisms through which these interventions produce their clinical benefits and identifying the factors that may maximize an individual's response to MFG and GCBT could improve the clinical benefits facilitated by these two interventions.
Looking for future studies?
Notify Me18 year–35 year
All sexes
Interventional
Not applicable
Tucson, Arizona, 85724, United States
Background
There is growing evidence that the majority of the psychosocial deterioration that accompanies psychotic disorders occurs during the first few years of illness and that the prevention or delay of early deterioration may be associated with a better course of illness. Two interventions which have been shown to improve the course of recent-onset psychosis are multifamily group psychoeducation [MFG] and group cognitive behavioral therapy [GCBT]. Both family psychoeducation and cognitive behavioral therapy have been recommended as components of usual care for psychotic disorders by the Schizophrenia Patient Oriented Research Team convened by the U.S. Department of Health and Human Services (10) as well as other international health organizations. However, like all treatments for psychotic disorders, neither MFG nor GCBT are perfect-some individuals who receive these interventions still experience a worsening of psychotic symptoms. Clarifying the mechanisms through which these interventions produce their clinical benefits and identifying the factors that may maximize an individual's response to MFG and GCBT could improve the clinical benefits facilitated by these two interventions.
Purpose and Objectives
The goal of this study is to clarify the mechanisms through which MFG and GCBT produce their clinical benefits (i.e., mediators) and identify the factors that may maximize an individual's response to these two empirically-validated interventions (i.e., moderators).
Methods
All participants will be provided with 2 years of of GCBT and MFG and will complete regular assessments with regard to clinical and functional outcomes as well as potential mediators and moderators of these outcomes.
Significance of the Study
Clarifying the mechanisms through which these interventions produce their clinical benefits and identifying the factors that may maximize an individual's response to MFG and GCBT could lead to improvements in the treatment of first-episode psychosis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(Individual with Recent-Onset Psychosis):
Exclusion Criterion (Individual with Recent Onset Psychosis)
Inclusion criteria
(Family Caregiver):
Exclusion Criterion (Family Caregiver)
weekly
twice monthly
Time frame: Baseline, 6 months, 12 months, 18 months, 24 months
General level of functioning to be assessed using the General Assessment of Functioning (GAF) scale
Time frame: Baseline, 6 months, 12 months, 18 months, 24 months
Self-reported physical health assessed using the RAND-36 Health Survey
Time frame: Baseline, 6 months, 12 months, 18 months, 24 months
Social and Vocational functioning to be assessed using the Social Functioning Scale
Time frame: Baseline, 6 months, 12 months, 18 months, 24 months
Stage of recovery assessed using the Stage of Recovery Instrument
Time frame: Baseline, 6 months, 12 months, 18 months, 24 months
Service utilization as assessed using the Service Utilization Record Form
Time frame: Baseline, 6 months, 12 months, 18 months, 24 months
Quality of Life as assessed using the WHO Quality of Life Scale Brief
University of Arizona
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01196286
Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features
Tucson, Arizona, United States
View Trial DetailsNCT04497857
Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features
Indianapolis, Indiana, United States
View Trial DetailsNCT03079024
Bipolar Disorder With Psychotic Features, Depression Psychotic Feature
Minneapolis, Minnesota, United States
View Trial DetailsNCT01259427
Behavior, Bipolar Disorder
Washington D.C., District of Columbia, United States
View Trial Details